Similarly, about 60%-70% of melanoma patients are unresponsive to anti-PD-1 monotherapy (nivolumab or pembrolizumab), and 40%-50% of patients are unresponsive to anti-CTLA-4 combination therapy (10). The gene discussed is CTLA4; the disease is melanoma.